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A commentary on
Peripartum cardiomyopathy in intensive care unit: an update 
by Dinic V, Markovic D, Savic N, Kutlesic M, Jankovic RJ. Front Med (2015) 2:82. doi: 10.3389/
fmed.2015.00082
We read with interest the article recently published by Dinic et al. entitled “Peripartum Cardiomyopathy 
in Intensive Care Unit: An Update” (1). However, we have some concerns about the article.
Our first concern is about the definition of peripartum cardiomyopathy (PPCM). The authors 
defined PPCM as the development of heart failure during the last month of pregnancy or within 
5 months after delivery. However, the restriction of the time frame to last month of pregnancy or 
first 5 months postpartum for diagnosis has been challenged (2). In a study by Elkayam et al., almost 
20% of the patients developed symptoms of heart failure and were diagnosed with PPCM earlier 
than the last gestational month (3). A comparison between patients with early presentation and 
those with traditional criteria of PPCM revealed no significant differences in age, ethnic background, 
obstetrical history, and rate of gestational hypertension. Maternal outcome, left ventricular function 
at the time of diagnosis, and its recovery over time were also similar between the two groups. These 
findings indicate that PPCM and pregnancy-associated cardiomyopathy are part of the same clinical 
spectrum, and some patients may present with PPCM symptoms earlier than the last gestational 
month. Hence, a position statement from a European Society of Cardiology working group on 
PPCM has eliminated the strict time limit to the diagnosis and expanded the definition of PPCM 
to “an idiopathic cardiomyopathy presenting with heart failure secondary to left ventricle systolic 
dysfunction toward the end of pregnancy or in the months following delivery, where no other cause 
of heart failure is found” (4). We think that PPCM is a diagnosis of exclusion and the time frame and 
echocardiographic cut-offs are arbitrary and can lead to underdiagnosis of PPCM.
Our second concern is about the duration of therapy in patients with PPCM. Recently, we 
have published results of 42 prospectively followed PPCM patients (5). Twenty patients (47.6%) 
recovered completely, 10 died (23.8%), and 12 (28.6%) had persistent left ventricular dysfunction. 
Average time to complete recovery was 19.3  months after initial diagnosis (3–42  months). Four 
patients (two patients with complete recovery and two patients with partial recovery) showed 
delayed deterioration (12, 24, 26, and 34 months after diagnosis) during the study period. Of the 
four patients with spontaneous deterioration of left ventricular function, two patients with partial 
recovery were receiving full-dosage heart failure treatment, but two patients with complete recovery 
stopped taking their medications after recovery, and had delayed deterioration at 24 and 34 months. 
The findings of late deterioration are very important and indicate the need for a close follow-up 
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with periodic determination of cardiac function in women in 
whom medications are discontinued after complete recovery. 
Due to probability of either delayed recovery or deterioration of 
left ventricular function in PPCM, long-term follow-up may be 
needed not only in non-recovered patients but also in patients 
with complete recovery.
Our last concern is about the use of levosimendan in PPCM. 
Although authors referred two case reports, they have omitted 
to mention the only randomized clinical trial evaluating the 
role of levosimendan in patients with PPCM. In a prospectively 
randomized study, we showed that the addition of levosimendan 
to conventional therapy did not improve the outcome in patients 
with PPCM (6).
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